PTC Therapeutics reports FY2024 revenue $807M above guidance; cash >$2B after Novartis deal

PTC THERAPEUTICS, INC.

2024-FY EPS reported -$4.73 revenue$806,780,000

FY2024 total revenue $806.8M, exceeding guidance; net loss $363.3M vs $626.6M prior year.
Cash and marketable securities $1.14B at Dec 31, 2024; >$2B after Jan 2025 Novartis PTC518 deal.
Four NDAs accepted by FDA in 2024; sepiapterin PDUFA July 29, 2025, vatiquinone priority review Aug 19, 2025.
FY2025 revenue guidance $600-800M; GAAP R&D+SG&A $805-835M; cash supports commercial and R&D plans.
DMD franchise revenue $144M in Q4; Translarna $93.7M, Emflaza $50.5M; Evrysdi royalties $203.9M in FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.